{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:38Z","timestamp":1793104178191,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8162\/A27047"],"award-info":[{"award-number":["C8162\/A27047"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8162\/A27047"],"award-info":[{"award-number":["C8162\/A27047"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Relative test accuracy of human papillomavirus (HPV) testing on self vs. clinician-collected samples may depend on the specific combination of a self-sampling device and HPV assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Five self-sampling workflows were studied within the routine English cervical screening programme; the cobas HPV DNA and APTIMA HPV mRNA assays with the Evalyn brush, Self Vaginal FLOQSwabs (FLOQSwabs) and the Multitest kit. To study test sensitivity, women were recruited at routine colposcopy appointments; to study test specificity, women were recruited at routine screening appointments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The estimated conditional relative sensitivity for high-grade cervical intraepithelial neoplasia (CIN2+) was 0.90 (90% CI: 0.84\u20130.94) for the Evalyn\u2009+\u2009cobas workflow, 0.94 (0.90\u20130.97) for FLOQSwabs\u2009+\u2009cobas, 0.77 (0.69\u20130.83) for Evalyn\u2009+\u2009APTIMA, 0.92 (0.85\u20130.96) for FLOQSwabs+APTIMA and 0.92 (0.86\u20130.96) for Multitest+APTIMA. The estimates of the relative specificity were 0.96 (0.95-0.98), 0.91 (0.90-0.93), 0.99 (0.97\u20131.01), 0.89 (0.87\u20130.92) and 0.87 (0.85\u20130.89), respectively. The specificity estimates were sensitive to the inclusion of certain subgroups of women. HPV detection rates were higher for all self-sample than clinician-sample workflows.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The relative test sensitivity of four self-sampling workflows including both DNA and mRNA HPV assays was relatively close to that associated with clinician-collected samples.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-025-03102-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:42:21Z","timestamp":1752136941000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HPValidate\u2014human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices"],"prefix":"10.1038","volume":"133","author":[{"given":"Christopher S.","family":"Mathews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sargent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Cuschieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-645X","authenticated-orcid":false,"given":"Matejka","family":"Rebolj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Brentnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasit","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"3102_CR1","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/ijc.27790","volume":"132","author":"PJ Snijders","year":"2013","unstructured":"Snijders PJ, Verhoef VMJ, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013;132:2223\u201336.","journal-title":"Int J Cancer"},{"key":"3102_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.34358","volume":"153","author":"M Rebolj","year":"2023","unstructured":"Rebolj M, Sargent A, Njor SH, Cuschieri K. Widening the offer of human papillomavirus self-sampling to all women eligible for cervical screening: Make haste slowly. Int J Cancer. 2023;153:8\u201319.","journal-title":"Int J Cancer"},{"key":"3102_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/09691413221092246","volume":"29","author":"H Drysdale","year":"2022","unstructured":"Drysdale H, Marlow LA, Lim A, Sasieni P, Waller J. Self-sampling for cervical screening offered at the point of invitation: a cross-sectional study of preferences in England. J Med Screen. 2022;29:194\u2013202.","journal-title":"J Med Screen."},{"key":"3102_CR4","doi-asserted-by":"publisher","first-page":"106900","DOI":"10.1016\/j.ypmed.2021.106900","volume":"154","author":"B Serrano","year":"2022","unstructured":"Serrano B, Ibanez R, Robles C, Peremiquel-Trillas P, de Sanjose S, Bruni L. Worldwide use of HPV self-sampling for cervical cancer screening. Prev Med. 2022;154:106900.","journal-title":"Prev Med."},{"key":"3102_CR5","unstructured":"FDA. FDA News Release; FDA Roundup: May 17, 2024. URL: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-roundup-may-17-2024. Accessed 18 June 2024."},{"key":"3102_CR6","unstructured":"BD. BD announces industry-first CE marked assay for HPV screening from at-home self-collected vaginal samples. URL: https:\/\/news.bd.com\/2021-05-13-BD-Announces-Industry-First-CE-Marked-Assay-for-HPV-Screening-from-At-Home-Self-Collected-Vaginal-Samples. Accessed 15 Dec 2021."},{"key":"3102_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/1055-9965.EPI-22-0712","volume":"32","author":"CA Aitken","year":"2022","unstructured":"Aitken CA, Inturrisi F, Kaljouw S, Nieboer D, Siebers AG, Melchers WJG, et al. Sociodemographic characteristics and screening outcomes of women preferring self-sampling in the Dutch cervical cancer screening programme: a population-based study. Cancer Epidemiol Biomark Prev. 2022;32:183\u201392.","journal-title":"Cancer Epidemiol Biomark Prev."},{"key":"3102_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/ijc.33888","volume":"150","author":"GA Stanczuk","year":"2022","unstructured":"Stanczuk GA, Currie H, Forson W, Baxter G, Lawrence J, Wilson A, et al. Self-sampling as the principal modality for population based cervical screening: five-year follow-up of the PaVDaG study. Int J Cancer. 2022;150:1350\u20136.","journal-title":"Int J Cancer"},{"key":"3102_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1055-9965.EPI-20-1226","volume":"30","author":"L Cadman","year":"2021","unstructured":"Cadman L, Reuter C, Jitlal M, Kleeman M, Austin J, Hollingworth T, et al. A randomized comparison of different vaginal self-sampling devices and urine for human papillomavirus testing-predictors 5.1. Cancer Epidemiol Biomark Prev. 2021;30:661\u20138.","journal-title":"Cancer Epidemiol Biomark Prev."},{"key":"3102_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2144\/btn-2022-0084","volume":"74","author":"L Connor","year":"2023","unstructured":"Connor L, Elasifer H, Sargent A, Bhatia R, Graham C, Cuschieri K. Influence of resuspension volume on dry sampling devices taken for human papillomavirus testing: implications for self-sampling. Biotechniques. 2023;74:77\u201384.","journal-title":"Biotechniques"},{"key":"3102_CR11","unstructured":"UK National Screening Committee. UK National Screening Committee consultation on modifying the NHS Cervical Screening Programmes in the four UK nations. URL: https:\/\/view-health-screening-recommendations.service.gov.uk\/document\/320\/download. Accessed 22 March 2024."},{"key":"3102_CR12","unstructured":"Stubbs R. Significant breakthrough\u2019 towards cervical screening self-sampling. URL: https:\/\/phescreening.blog.gov.uk\/2020\/12\/21\/significant-breakthrough-towards-cervical-screening-self-sampling\/. Accessed 7 February 2021."},{"key":"3102_CR13","unstructured":"Mills C. HPValidate cervical screening self-sampling study nears completion. URL: https:\/\/nationalscreening.blog.gov.uk\/2023\/06\/21\/hpvalidate-cervical-screening-self-sampling-study-nears-completion\/. Accessed 22 March 2024."},{"key":"3102_CR14","unstructured":"Stubbs R. Recruitment for cervical screening self-sampling study now underway. URL: https:\/\/phescreening.blog.gov.uk\/2021\/04\/28\/cervical-screening-self-sampling-study\/. Accessed 22 March 2024."},{"key":"3102_CR15","unstructured":"British Association for Cytopathology. HPV updates from around the United Kingdom. In: SCAN, page 14, Vol. 30, 2 October 2019. URL: http:\/\/www.britishcytology.org.uk\/resources\/eSCAN_30-2_Oct_2019_.pdf. Accessed 17 May 2021."},{"key":"3102_CR16","unstructured":"Stubbs R. Significant landmark as primary HPV screening is offered across England. URL: https:\/\/phescreening.blog.gov.uk\/2020\/01\/23\/significant-landmark-as-primary-hpv-screening-is-offered-across-england\/. Accessed 22 Feb 2021."},{"key":"3102_CR17","unstructured":"Gov.uk. Guidance: cervical screening: acceptable HPV tests. Updated 24 November 2023. URL: https:\/\/www.gov.uk\/government\/publications\/cervical-screening-acceptable-hpv-tests\/cervical-screening-acceptable-hpv-tests. Accessed 22 March 2024."},{"key":"3102_CR18","unstructured":"Gov.uk. Guidance. NHS Cervical Screening Programme\u2014good practice guidance for sample takers (updated 13 June 2024). URL: https:\/\/www.gov.uk\/government\/publications\/nhs-cervical-screening-programme-good-practice-guidance-for-sample-takers\/nhs-cervical-screening-programme-good-practice-guidance-for-sample-takers. Accessed 18 June 2024."},{"key":"3102_CR19","unstructured":"Gov.uk. Guidance. Cervical screening: laboratory testing for human papillomavirus. URL: https:\/\/www.gov.uk\/government\/publications\/cervical-screening-laboratory-testing-for-human-papillomavirus. Accessed 18 June 2024."},{"key":"3102_CR20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41416-019-0547-x","volume":"121","author":"M Rebolj","year":"2019","unstructured":"Rebolj M, Brentnall AR, Mathews C, Denton K, Holbrook M, Levine T, et al. 16\/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br J Cancer. 2019;121:455\u201363.","journal-title":"Br J Cancer"},{"key":"3102_CR21","unstructured":"Gov.uk. Guidance. Cervical screening: programme and colposcopy management. URL: https:\/\/www.gov.uk\/government\/publications\/cervical-screening-programme-and-colposcopy-management. Accessed 18 June 2024."},{"key":"3102_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/09691413221090892","volume":"29","author":"A Castanon","year":"2022","unstructured":"Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. COVID-19 disruption to cervical cancer screening in England. J Med Screen. 2022;29:203\u20138.","journal-title":"J Med Screen."},{"key":"3102_CR23","unstructured":"Copan. Copan instruction sheet HP1031C.LANG01 REV.03 Date 2020.03."},{"key":"3102_CR24","unstructured":"Rovers Medical Devices. Evalyn Brush. Instructions for the home test. URL: https:\/\/www.roversmedicaldevices.com\/wp-content\/uploads\/2016\/07\/ROVER0175_FOLDER-EVALYN-GEBRUIKSAANWIJZING-EN_S3_V3.pdf. Accessed 26 June 2024."},{"key":"3102_CR25","unstructured":"Hologic. Vaginal swab sample collection: aptima multitest swab specimen collection kit. Patient Quick Reference Guide. (Undated)."},{"key":"3102_CR26","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/1471-0528.17058","volume":"129","author":"M Rebolj","year":"2022","unstructured":"Rebolj M, Mathews CS, Pesola F, Cuschieri K, Denton K, Kitchener H. Age-specific outcomes from the first round of HPV screening in unvaccinated women: observational study from the English cervical screening pilot. BJOG. 2022;129:1278\u201388.","journal-title":"BJOG"},{"key":"3102_CR27","doi-asserted-by":"publisher","first-page":"111227","DOI":"10.1016\/j.jclinepi.2023.111227","volume":"166","author":"AR Brentnall","year":"2024","unstructured":"Brentnall AR, Cuschieri K, Sargent A, Berkhof J, Rebolj M. Staged design recommendations for validating relative sensitivity of self-sample human papillomavirus tests for cervical screening. J Clin Epidemiol. 2024;166:111227.","journal-title":"J Clin Epidemiol."},{"key":"3102_CR28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jclinepi.2009.08.024","volume":"63","author":"A Hayen","year":"2010","unstructured":"Hayen A, Macaskill P, Irwig L, Bossuyt P. Appropriate statistical methods are required to assess diagnostic tests for replacement, add-on, and triage. J Clin Epidemiol. 2010;63:883\u201391.","journal-title":"J Clin Epidemiol."},{"key":"3102_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ijc.34014","volume":"151","author":"AR Brentnall","year":"2022","unstructured":"Brentnall AR, Rebolj M. Comments on: \u201cMeta-analysis of agreement\/concordance statistics in studies comparing self- vs clinician-collected samples for HPV testing in cervical cancer screening\u201d. Int J Cancer. 2022;151:481\u20133.","journal-title":"Int J Cancer"},{"key":"3102_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41416-022-01791-w","volume":"127","author":"M Rebolj","year":"2022","unstructured":"Rebolj M, Pesola F, Mathews C, Mesher D, Soldan K, Kitchener H. The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot. Br J Cancer. 2022;127:278\u201387.","journal-title":"Br J Cancer"},{"key":"3102_CR31","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.lanepe.2021.100235","volume":"11","author":"F Inturrisi","year":"2021","unstructured":"Inturrisi F, Aitken CA, Melchers WJG, van den Brule AJC, Molijn A, Hinrichs JWJ, et al. Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Reg Health Eur. 2021;11:100235.","journal-title":"Lancet Reg Health Eur."},{"key":"3102_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.12688\/openreseurope.14344.2","volume":"2","author":"C Giubbi","year":"2022","unstructured":"Giubbi C, Martinelli M, Vallini I, Paganoni S, Dafa\u2019alla T, Perdoni F, et al. Human papillomavirus (HPV) detection in vaginal self-samples: evaluation of eNat(R) as an alternative suspension medium to ThinPrep(R)PreservCyt(R) for vaginal swabs. Open Res Eur. 2022;2:35.","journal-title":"Open Res Eur."},{"key":"3102_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1158\/1055-9965.EPI-22-1041","volume":"32","author":"M Arbyn","year":"2023","unstructured":"Arbyn M, Costa S, Latsuzbaia A, Kellen E, Girogi Rossi P, Cocuzza CE, et al. HPV-based cervical cancer screening on self-samples in the netherlands: challenges to reach women and test performance questions. Cancer Epidemiol Biomark Prev. 2023;32:159\u201363.","journal-title":"Cancer Epidemiol Biomark Prev."},{"key":"3102_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jviromet.2019.04.015","volume":"270","author":"C Borgfeldt","year":"2019","unstructured":"Borgfeldt C, Forslund O. Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. J Virol Methods. 2019;270:18\u201320.","journal-title":"J Virol Methods"},{"key":"3102_CR35","unstructured":"Marlow L, Waller J. Acceptability of self-collecting vaginal samples in HPValidate and attitudes to self-sampling as a choice in future cervical screening. https:\/\/www.qmul.ac.uk\/fmd\/media\/smd\/documents\/research\/hpv-self-collection-test-acceptability-report-hpvalidate-lot2.pdf. Last accessed: 3 July 2025."},{"key":"3102_CR36","doi-asserted-by":"publisher","first-page":"k4823","DOI":"10.1136\/bmj.k4823","volume":"363","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018;363:k4823.","journal-title":"BMJ"},{"key":"3102_CR37","doi-asserted-by":"publisher","first-page":"l240","DOI":"10.1136\/bmj.l240","volume":"364","author":"M Rebolj","year":"2019","unstructured":"Rebolj M, Rimmer J, Denton K, Tidy J, Mathews C, Ellis K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;364:l240.","journal-title":"BMJ"},{"key":"3102_CR38","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/S0140-6736(01)06809-X","volume":"358","author":"MA Nobbenhuis","year":"2001","unstructured":"Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001;358:1782\u20133.","journal-title":"Lancet"},{"key":"3102_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.1433","volume":"201","author":"PJ Snijders","year":"2003","unstructured":"Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003;201:1\u20136.","journal-title":"J Pathol."},{"key":"3102_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/cyt.12451","volume":"28","author":"M Rebolj","year":"2017","unstructured":"Rebolj M, Njor S, Lynge E, Preisler S, Ejegod D, Rygaard C, et al. Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. Cytopathology. 2017;28:419\u201328.","journal-title":"Cytopathology"},{"key":"3102_CR41","doi-asserted-by":"publisher","first-page":"e068776","DOI":"10.1136\/bmj-2021-068776","volume":"377","author":"M Rebolj","year":"2022","unstructured":"Rebolj M, Cuschieri K, Mathews CS, Pesola F, Denton K, Kitchener H. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ. 2022;377:e068776.","journal-title":"BMJ"},{"key":"3102_CR42","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(22)00294-7","volume":"23","author":"M Arbyn","year":"2022","unstructured":"Arbyn M, Simon M, de Sanjos\u00e9 S, Clarke MA, Poljak M, Rezhake R, et al. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis. Lancet Oncol. 2022;23:950\u201360.","journal-title":"Lancet Oncol"},{"key":"3102_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/IGC.0b013e318280f3bc","volume":"23","author":"L Nieves","year":"2013","unstructured":"Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer. 2013;23:513\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"3102_CR44","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/aogs.12960","volume":"95","author":"KC Asciutto","year":"2016","unstructured":"Asciutto KC, Henic E, Darlin L, Forslund O, Borgfeldt C. Follow up with HPV test and cytology as test of cure, 6 months after conization, is reliable. Acta Obstet Gynecol Scand. 2016;95:1251\u20137.","journal-title":"Acta Obstet Gynecol Scand."},{"key":"3102_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/ijgo.12628","volume":"143","author":"V Senkomago","year":"2018","unstructured":"Senkomago V, Ting J, Kwatampora J, Gukare H, Mugo N, Kimani J, et al. High-risk HPV-RNA screening of physician- and self-collected specimens for detection of cervical lesions among female sex workers in Nairobi, Kenya. Int J Gynaecol Obstet. 2018;143:217\u201324.","journal-title":"Int J Gynaecol Obstet."},{"key":"3102_CR46","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1136\/ijgc-2023-004424","volume":"33","author":"N Phoolcharoen","year":"2023","unstructured":"Phoolcharoen N, Areeruk W, Kantathavorn N, Tiyayon J, Chittithaworn S, Wetcho T, et al. Self- and physician-collected high-risk human papillomavirus (HPV) testing to detect high-grade cervical lesions among Thai women. Int J Gynecol Cancer. 2023;33:1354\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"3102_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcv.2018.02.002","volume":"101","author":"KC Asciutto","year":"2018","unstructured":"Asciutto KC, Ernstson A, Forslund O, Borgfeldt C. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. J Clin Virol. 2018;101:69\u201373.","journal-title":"J Clin Virol."},{"key":"3102_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/OLQ.0000000000000125","volume":"41","author":"M Chernesky","year":"2014","unstructured":"Chernesky M, Jang D, Gilchrist J, Elit L, Lytwyn A, Smieja M, et al. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6\/E7 messenger RNA in cervical and vaginal samples. Sex Transm Dis. 2014;41:365\u20138.","journal-title":"Sex Transm Dis."},{"key":"3102_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jcv.2015.11.005","volume":"74","author":"V Senkomago","year":"2016","unstructured":"Senkomago V, Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, Smith JS. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J Clin Virol. 2016;74:26\u201331.","journal-title":"J Clin Virol."},{"key":"3102_CR50","doi-asserted-by":"publisher","first-page":"102672","DOI":"10.1016\/j.eclinm.2024.102672","volume":"73","author":"AWW Lim","year":"2024","unstructured":"Lim AWW, Deats K, Gambell J, Lawrence A, Lei J, Lyons M, et al. Opportunistic offering of self-sampling to non-attenders within the English cervical screening programme: a pragmatic, multicentre, implementation feasibility trial with randomly allocated cluster intervention start dates (YouScreen). eClinicalMedicine. 2024;73:102672.","journal-title":"eClinicalMedicine"},{"key":"3102_CR51","doi-asserted-by":"publisher","first-page":"e86835","DOI":"10.1371\/journal.pone.0086835","volume":"9","author":"M Rebolj","year":"2014","unstructured":"Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. PLoS ONE. 2014;9:e86835.","journal-title":"PLoS ONE"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03102-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:52:57Z","timestamp":1757209977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03102-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,21]]}},"alternative-id":["3102"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03102-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"21 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AS: A member of various expert groups providing advice to the NHS Cervical Screening Programme including on HPV self-sampling; holds an honorary contract with the University of Manchester to support research into HPV testing in urine samples and Professional Clinical Advisor to the NHS Cervical Screening Programme. KC: KC\u2019s institution has received research funding or gratis consumables to support research from the following commercial entities in the last 3 years: Abbott, Euroimmun, GeneFirst, Qiagen, Hiantis, Seegene, Roche, Hologic, Barinthus Biotherapeutics PLC & Daye. KC has attended advisory board meetings for Hologic, Becton Dickinson and Barinthus Biotherapeutics PLC (no personal renumeration received; UK travel supported for Hologic). MR: Public Health England and the UK National Screening Committee provided funding for the epidemiological evaluation of various cervical screening studies, including HPValidate; current and former member of various expert groups providing advice to NHSE cervical screening programme; attended meetings with HPV test manufacturers; fees for attendance at advisory board and other meetings organised by Hologic, shared with employer, including travel cost reimbursement if applicable. AB: Member of the UK National Screening Committee Research and Methodology subgroup. AM, ChMi, CaMa, AMW: Employed by the Department of Health and Social Care in England. KH: Member of the Laboratory Technology Group advising the English cervical screening programme. TJ: TJ\u2019s institution has received gratis consumables to support research from the following commercial entities in the last 3 years: Roche and Hologic. The institution has received funding for Health promotion from Roche. Has attended meetings organised by Hologic and was reimbursed travel costs. KE: Former member of the Advisory Committee for Cervical Screening and British Association for Cytopathology. KE\u2019s institution has received gratis consumables to support research from the following commercial entities in the last 3 years: Roche and Hologic. The institution has received funding for Health promotion from Roche. Has attended meetings organised by Hologic and was reimbursed travel costs. KD: Adviser to Public Health England and subsequently NHS England; this position is funded by Public Health England\/NHS England as a secondment from her main employment. She chairs the NHS England Laboratory Clinical professional group, and formerly the HPV development group and several groups related to the evaluation of self-sampling. Expert medicolegal reports prepared for claimants and defendants including in cases of cervical cancer. Advisor to Ontario Health on cervical screening issues. Consultancy services to Hologic, a manufacturer of HPV and cytology tests, commenced after this work was completed. All other authors: The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was granted by Stanmore NHS Health Research Authority on 27 October 2020 (reference: 20\/LO\/1009). All women provided written informed consent. The study was included in the NIHR register (CPMS ID: 47399). IRAS record number: 286052. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}